EN DE ES FR IT Primary Menu Business Model Outsourced R&D – products acquired from R&D companies. No in-house manufacturing to reduce risk and costs. Scalable business model with low capex needs. Fast-growing global specialist company Established in 2010, Primex owns, markets and sells high-quality anaesthetic pharmaceuticals worldwide. Primex’s activities consist of managing two core functions: global regulatory affairs and global distribution and marketing. Manufacturing is outsourced to partners under the strictest quality controls, ensuring full financial flexibility, as a result, the company does not support R&D risk. The company is building a strong niche offering in anaesthetics and recently acquired global rights to OZALIN, a drug addressing unmet needs in paediatric sedation. Primex has experienced strong growth since its foundation, developing a lean business model enabling quick scalability through acquisitions of new drugs. TOP © 2018 Primex Pharmaceuticals. All Rights Reserved. Privacy Policy | Conditions of Use | Drug Safety Reporting Privacy Policy

EN DE ES FR IT Primary Menu Board Members PANU PAAPPANEN Chairman JULIANNA BORSOS Board Member PETRI LAINE Board Member JANY MENGELKAMP Board Member & Co-Founder JOSTEIN DAVIDSEN Board Member Senior Leadership Team ALAN KNOX Group CEO since 2019 Previously Head of Sales & Marketing Primex since 2016 ERNESTO ALEGRIA CFO since 2016 TOMASO DAMENO Head of Operations since 2018 LINDA LIITOLA Head of Legal Affairs since 2014 TOP © 2018 Primex Pharmaceuticals. All Rights Reserved. Privacy Policy | Conditions of Use | Drug Safety Reporting Privacy Policy

EN DE ES FR IT Primary Menu RECOFOL ® propofol satisfying anaesthesia & ICU sedation RECOFOL – 1st branded generic propofol Intravenous anaesthetic, which is used by intensive care units, surgeries and clinics. RECOFOL can be used from light sedation to total anaesthesia. RECOFOL active ingredient is propofol, which is the most widely used intravenous anaesthetic with growing global demand. Primex is expanding RECOFOL geographically with regional partners. RECOFOL N Recofol N is a Bayer-originated intravenous anaesthetic, which is used by intensive care units, surgeries and clinics. Primex Pharmaceuticals obtained Recofol N through an acquisition from Bayer in 2011. Recofol N’s active ingredient is propofol. Recofol N is manufactured in Europe. Recofol EDTA Recofol EDTA (propofol plus EDTA) is propofol with the preservative EDTA as an antimicrobial retardant, as required by the FDA and other authorities and is manufactured in EU. TOP © 2018 Primex Pharmaceuticals. All Rights Reserved. Privacy Policy | Conditions of Use | Drug Safety Reporting Privacy Policy